A New Urine Test for Early Detection of Lung Cancer
A groundbreaking urine test that can detect lung cancer years before symptoms appear is on the horizon, with experts suggesting it could be available within the next five years. This development offers hope for a disease that claims over 35,000 lives in the UK annually and is notoriously difficult to diagnose at an early stage. Most cases are only identified once the cancer has spread, making treatment significantly more challenging.
The new test, developed by scientists funded by Cancer Research UK, identifies toxic proteins in urine that may signal the presence of lung cancer long before any symptoms manifest. Professor Ljiljana Fruk from the University of Cambridge expressed optimism about the test’s potential, stating she hopes to see it implemented across the NHS within the next five years. She believes this innovation could make a meaningful difference for those at risk of this devastating disease.
This advancement comes shortly after NHS data showed a significant increase in early lung cancer diagnoses due to a supermarket-based screening initiative. The program uses mobile screening trucks stationed in sports stadiums and busy high streets to detect more than 10,000 lung cancers since its launch in 2019. Nearly 50,000 people in the UK are diagnosed with lung cancer each year, making it the third most common cancer and the leading cause of cancer-related deaths.
Early diagnosis is crucial for improving survival rates, as patients diagnosed at the earliest stages have nearly 13 times higher chances of surviving for five years compared to those diagnosed later. However, lung cancer rarely presents symptoms in its initial stages because the lungs lack nerve endings. As a result, most cases are detected after the cancer has spread, causing symptoms like persistent coughs, chest pain, unexplained weight loss, and fatigue.
Only 11% of lung cancer patients survive 10 or more years after diagnosis. The latest urine test aims to change this by detecting the disease before it spreads. The test looks for so-called ‘zombie’ cell proteins, which are cells that refuse to die but also cannot grow or divide. These cells release toxic chemicals that damage surrounding tissue and promote the growth of cancer cells.
Scientists have developed an injectable sensor that releases a detectable compound into urine when it interacts with zombie cell proteins, indicating their presence. This technology, described in the journal Nature Ageing, may also be useful for detecting other lung diseases such as pulmonary fibrosis.
Professor Fruk emphasized that while the sensor has not yet been tested in humans, the next step is clinical trials, which could take several years before it reaches patients. However, she sees this as a significant first step that could eventually be used in GP surgeries and hospitals to detect recurrence in this hard-to-treat cancer much earlier.
Professor Robert Rintoul of the Department of Oncology and co-lead for the Cancer Research UK Cambridge Centre Thoracic Cancer Programme highlighted the need for novel approaches to improve patient outcomes. He stated that this work forms the basis for testing within clinical trials, with the aim of future use in clinics.
Patrick Keely, a spokesman for Cancer Research UK in the east of England, praised the innovative urine test as part of a golden age of research. He noted that new technologies are opening doors to discoveries that could transform cancer detection and treatment.
The NHS recently announced that 10,678 patients were diagnosed with lung cancer through its supermarket screening initiative, with the majority caught in the earliest stages. The program, aimed at improving Britain’s poor lung cancer survival rates, offers an “MOT for their lungs” to people aged 55 to 74 with a history of smoking. Areas with the highest death rates from lung cancer were prioritized, with half of England’s most at-risk individuals now having been screened for the deadly disease.
